Reference · cited facts
PT-141
Bremelanotide / VyleesiHalf-life ≈11 hoursFDA-approvedReviewed July 2026
Educational information and a math tool only — not medical advice, a dose recommendation, or an endorsement of peptide use. Consult a licensed healthcare provider before starting, stopping, or changing anything.
Class / mechanism
PT-141 (bremelanotide) is a melanocortin-receptor (MC3/MC4) agonist.
SOURCE [1]
Regulatory status
FDA-approved as Vyleesi (June 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — any other use is off-label. The approved product is a 1.75 mg single-dose auto-injector, not a powder to reconstitute. Not explicitly listed on WADA's 2026 Prohibited List. As of 2026-07-13 and subject to change.
FDA · July 2026
Reported half-life
≈11 hours
PUBMED
Human evidence
Established (FDA-approved)
LITERATURE
What the literature reports
- PT-141 (bremelanotide) is a melanocortin-receptor (MC3/MC4) agonist.
- Its published half-life is about 11 hours (roughly 10.9 hours per the FDA Vyleesi prescribing information, section 12.3).
- It is FDA-approved as Vyleesi for a narrow indication (HSDD in premenopausal women); the approved product is a prefilled 1.75 mg auto-injector, while research-grade vials are a different, non-approved material.
- It is not explicitly listed on WADA's 2026 Prohibited List.
Honest caveats
- • FDA approval is for one narrow indication (HSDD in premenopausal women) — any other use is off-label.
- • The FDA-approved product is a prefilled auto-injector; reconstituted research-grade material is not the approved product.
- • Reference facts only — no dose, protocol, or benefit is stated or implied.
Reconstitution calculator
Enter your own vial size, BAC water and target dose — get exact syringe units.
Sources